Post-operative radioiodine therapy (RaIT) as adjuvant therapy in low–intermediate risk differentiated thyroid cancer

摘要: For many years, thyroid surgery and radioiodine therapy for remnant ablation (i.e. post-operative RaIT) have been the first-line therapeutic approaches in differentiated carcinoma (DTC). In latest American Thyroid Association Guidelines (ATA), RaIT is not indicated low-risk DTC, while no clear indication postulated regarding low- to intermediate-risk patients, even if it discouraged most of them. The European Nuclear Medicine did endorse ATA guidelines since role nuclear medicine was marginalized patients affected by or cancers. present review evaluates adjuvant low DTC patients. terms therapy, treatment, ablation, treatment were used search MEDLINE papers published from January 2008 May 2018. Among 895 papers, we considered 8 which underwent results post-therapy whole body scans (pT-WBS) reported. pT-WBS identified metastases 282 out 1622 (17.4%). All except 28 metastatic either DTC. Metastases confirmed (targeted)-morphological and/or morphofunctional morphometabolic studies about 40% According presented data, slightly less than 20% showed at pT-WBS. Thus, our opinion should be as an also